3Ueda H, Ikegami H, Yamato E, et al. The NSY Mouse: a new animal model of spontaneous NIDDM with moderate obesity[J].Diabetologia , 1995,38 : 503
4Rackietan N, Rackietan M L, Nadkarni M R. Studies on diabetogenic action of streptozocin (NSC-37917) [J ]. Cancer Chemother Rep, 1993,29:91
5Pettepher C C, Ledoux S P, Bohr V A, et al. Repair of Alkalilabile sites within the mitochondrial DNA of RINr 38 cells after exposure to the nitrosourea streptozotocin[J]. J Bio Chem,1991,266:3113
6Lupi R, Dotta F, Marscella L, et al. Prolonged exposure to free fatty acids has cytosatatic and pro-apototic effects on human pancreastic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway and Bcl-2redulated[J]. Diabetes, 2002,51 : 1437
7Mauricio D, Mandrup-Palsen T. Apoptosis and the pathogenesis of IDDM: a question of life and death[J]. Diabetes, 1998,47:1537
8Liuk, Parterson A J, Chin E, et al. Glucose stimulates protein modification by o-linked GlcNAC pancreastic beta cell: Linkage of o-linked GlcNAC to bete cell death [J]. PNAS, 2000,97(6):2820
9Amos A F, Mc Carty D J, Zim Met P [J]. The rising global burden of diabetes and its complications :estimates and projections to the year 2010[J]. Diabet Med, 1997,14(Suppl 5) :SI
10Baylis C, Atzpodien EA, Freshour G, et al. Peroxisome proliferator activated receptor L gamma agonist provides superior renal protection versus angiotensin - converting enzyme inhibition in a rat model of type 2 diabetes with obesity [J]. J Pharmacol Exp Ther, 2003, 307 ( 3 ) : 854 -860.
